Literatura científica selecionada sobre o tema "Amyotrophic lateral sclerosis – patients"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Índice
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Amyotrophic lateral sclerosis – patients".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Amyotrophic lateral sclerosis – patients"
Nakayama, Yui, Satoru Morimoto, Misao Yoneda, Shigeki Kuzuhara e Yasumasa Kokubo. "Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex". Journal of Neurodegenerative Diseases 2013 (27 de março de 2013): 1–4. http://dx.doi.org/10.1155/2013/679089.
Texto completo da fonteFreischmidt, Axel, Kathrin Müller, Lisa Zondler, Patrick Weydt, Alexander E. Volk, Anže Lošdorfer Božič, Michael Walter et al. "Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers". Brain 137, n.º 11 (5 de setembro de 2014): 2938–50. http://dx.doi.org/10.1093/brain/awu249.
Texto completo da fonteVoitenkov, Vladislav B., e E. V. Ekusheva. "Pain in amyotrophic lateral sclerosis". Journal of Clinical Practice 10, n.º 2 (17 de agosto de 2019): 66–73. http://dx.doi.org/10.17816/clinpract10266-73.
Texto completo da fonteLi, Lian, Jie Liu e Hua She. "Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis". CNS & Neurological Disorders - Drug Targets 18, n.º 5 (23 de setembro de 2019): 366–71. http://dx.doi.org/10.2174/1871527318666190409103831.
Texto completo da fonteIngre, Caroline, Lin Chen, Yiqiang Zhan, Jet Termorshuizen, Li Yin e Fang Fang. "Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis". Neurology 94, n.º 17 (27 de março de 2020): e1835-e1844. http://dx.doi.org/10.1212/wnl.0000000000009322.
Texto completo da fonteGeevasinga, Nimeshan, James Howells, Parvathi Menon, Mehdi van den Bos, Kazumoto Shibuya, José Manuel Matamala, Susanna B. Park, Karen Byth, Matthew C. Kiernan e Steve Vucic. "Amyotrophic lateral sclerosis diagnostic index". Neurology 92, n.º 6 (11 de janeiro de 2019): e536-e547. http://dx.doi.org/10.1212/wnl.0000000000006876.
Texto completo da fonteSathasivam, Sivakumar. "Managing patients with amyotrophic lateral sclerosis". European Journal of Internal Medicine 20, n.º 4 (julho de 2009): 355–58. http://dx.doi.org/10.1016/j.ejim.2008.09.002.
Texto completo da fonteVerhey, F. R. J., F. W. Vreeling e J. Jolles. "Dementia and Amyotrophic Lateral Sclerosis". Acta Neuropsychiatrica 4, n.º 1 (março de 1992): 17–20. http://dx.doi.org/10.1017/s0924270800034967.
Texto completo da fonteCividini, Camilla, Silvia Basaia, Edoardo G. Spinelli, Elisa Canu, Veronica Castelnovo, Nilo Riva, Giordano Cecchetti et al. "Amyotrophic Lateral Sclerosis–Frontotemporal Dementia". Neurology 98, n.º 4 (1 de dezembro de 2021): e402-e415. http://dx.doi.org/10.1212/wnl.0000000000013123.
Texto completo da fonteOliveira Filho, Ademar Francisco de, Gêssyca Adryene de Menezes Silva e Débora Milenna Xavier Almeida. "Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review". Einstein (São Paulo) 14, n.º 3 (setembro de 2016): 431–34. http://dx.doi.org/10.1590/s1679-45082016rb3594.
Texto completo da fonteTeses / dissertações sobre o assunto "Amyotrophic lateral sclerosis – patients"
Bradley, Lloyd John. "Mitochondrial abnormalities in remote tissues of patients with amyotrophic lateral sclerosis". Thesis, University College London (University of London), 2006. http://discovery.ucl.ac.uk/1445375/.
Texto completo da fonteKasi, Patrick K. "Characterization of motor unit discharge rate in patients with amyotrophic lateral sclerosis". Worcester, Mass. : Worcester Polytechnic Institute, 2009. http://www.wpi.edu/Pubs/ETD/Available/etd-050409-062647/.
Texto completo da fonteLee, Rena J. "Study of trace and minor elements in ALS (amyotrophic lateral sclerosis) patients". Thesis, Massachusetts Institute of Technology, 1994. http://hdl.handle.net/1721.1/36492.
Texto completo da fonteOudenot, Hélèna. "Indirect Estimation of Persistent Inward Currents in Patients with Amyotrophic Lateral Sclerosis". Thesis, KTH, Tillämpad fysik, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-192844.
Texto completo da fonteTeyssou, Elisa. "Analyses génétiques et fonctionnelles de nouveaux gènes incriminés dans la Sclérose Latérale Amyotrophique (SLA) Genetic analysis of matrin 3 gene in French amyotrophic lateral sclerosis patients and frontotemporal lobar degeneration with amyotrophic lateral sclerosis patients Genetic analysis of CHCHD10 in French familial amyotrophic lateral sclerosis patients". Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066738.
Texto completo da fonteThe fatal Amyotrophic Lateral Sclerosis (ALS) motor neuron disease is characterized by the degeneration of upper and lower motor neurons. Most ALS cases are sporadic (SALS) whereas ~10% are familial (FALS). A growing number of genes has been identified in ALS and represent 70% of FALS and 10% of SALS. The aims of this project were to analyze the contribution of 6 rare genes in a large population of French ALS patients and to study the pathogenic impact of some identified variants.The first part of this work was dedicated to the genetic analysis of MATR3, CHCHD10, SS18L1, SQSTM1, UBQLN2 and PFN1 genes. No causing variants were identified for MATR3 and CHCHD10 while 2 new variants, probably pathogenic, were identified for SS18L1, as well as 4 mutations for SQSTM1, 5 for UBQLN2 and 2 already reported mutations for PFN1. These analyses also highlighted a genetic overlap between ALS and other diseases: the Paget disease of bone for SQSTM1 and spastic paraplegia for UBQLN2. The second part of this work was to study the pathogenicity of some of the mutations identified in SQSTM1, UBQLN2 and PFN1 genes using analyses of (i) inclusions in ALS patient post-mortem tissue, (ii) protein expression and degradation pathways in patient lymphoblasts and/or (iii) cellular consequences after in vitro and in vivo overexpression. Our results showed prominent aggregation of mutant SQSTM1 (involved in autophagosomes formation), impaired lysosomal degradation and disrupted protein binding to HSP70 for mutant UBQLN2 and deregulated alternative autophagy and mitophagy pathways for mutant PFN1. Our results (i) precised the contribution of several genes in French ALS patients, (i) documented the genetic overlap between ALS and other diseases and (iii) highlighted the role of protein degradation pathways, especially autophagy, in the pathogenesis of ALS
Lemoignan, Josée. "Decision-making for assisted ventilation in amyotrophic lateral sclerosis". Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=101862.
Texto completo da fonteAchille, Marie A. "Attitudes toward assisted suicide among patients with amyotrophic lateral sclerosis and their caregivers". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape10/PQDD_0023/NQ51830.pdf.
Texto completo da fonteCamara, Mafalda Dias de Medeiros Vale da. "Coherence and phase locking disruption in electromyograms of patients with amyotrophic lateral sclerosis". Master's thesis, Faculdade de Ciências e Tecnologia, 2013. http://hdl.handle.net/10362/10950.
Texto completo da fonteIn motor neuron disease, the aim of therapy is to prevent or slow neuronal degeneration and early diagnosis is thus essential. Hypothesising that beta-band (15-30 Hz) is a measure of pathways integrity as shown in literature, coherence and PLF could be used as an electrophysiological indicator of upper and lower neuron integrity in patients with ALS. Before further analysis, synthetic EMG signals were computed to verify the used algorithm. Coherence and PLF analyses were performed for instants of steady contraction from contra and ipsilateral acquisitions. Ipsilateral acquisitions were performed for one member of each group and results present significant differences between both groups. Contrarily, contralateral acquisitions were performed on 6 members of each group and results present no significant differences. PLF analysis was computed for ipsilateral acquisitions and, similarly to coherence, results show significant differences between both groups. PLF was also analysed for contralateral acquisitions, and results show no significant differences within groups, as expected since no coherence was found for the same acquisitions. So, while control subjects present no neuronal or muscular problems and therefore higher synchrony and coherence for beta-band frequencies, patients with ALS do not present synchronism or coherence in any frequency, specially for beta-band. All results allowed to conclude that contralateral coherence is not a good measure of corticospinal pathways integrity. However, ipsilateral acquisitions show promising results and it is possible to affirm that ipsilateral measurements may reflect neuronal degeneration. For future work is suggested a deeper analysis of PLF, that appear to have potential as a quantitative test of upper and lower neuron integrity related to ALS.
BENEDETTI, S. DE. "SPORADIC AMYOTROPHIC LATERAL SCLEROSIS IN PATIENTS WITH COMMON GEOGRAPHICAL ORIGIN: A MULTIDISCIPLINARY STUDY". Doctoral thesis, Università degli Studi di Milano, 2017. http://hdl.handle.net/2434/486489.
Texto completo da fonteOsei-Lah, Abena Dansoa. "Intracortical excitability is altered in patients with amyotrophic lateral sclerosis : a transcranial magnetic stimulation study". Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415039.
Texto completo da fonteLivros sobre o assunto "Amyotrophic lateral sclerosis – patients"
Hiroshi, Mitsumoto, ed. Amyotrophic lateral sclerosis: A guide for patients and families. 3a ed. New York, NY: Demos Health, 2009.
Encontre o texto completo da fonteHiroshi, Mitsumoto, e Munsat Theodore L. 1930-, eds. Amyotrophic lateral sclerosis: A guide for patients and families. 2a ed. New York: Demos, 2001.
Encontre o texto completo da fonteParker, James N., e Philip M. Parker. The official patient's sourcebook on amyotrophic lateral sclerosis. Editado por Icon Group International Inc. San Diego, Calif: Icon Health Publications, 2003.
Encontre o texto completo da fonteT, Caroscio James, ed. Amyotrophic lateral sclerosis: A guide to patient care. New York: Thieme, 1986.
Encontre o texto completo da fonteDavid, Oliver. Motor neurone disease. 2a ed. London: Royal College of General Practitioners, 1994.
Encontre o texto completo da fonteSŭng-il, Pak, ed. Nun ŭro hŭimang ŭl ssŭda: Lugerik kwa matsŏ ssaun kijŏk ŭi kŏin Pak Sŭng-il ŭi hŭimang ilgi. Sŏul-si: Ungjin Chisik Hausŭ, 2009.
Encontre o texto completo da fonteKoka, Halil. Bana ALS teşhisi koydular: Bir ALS hastasının umut dolu savaşı. İstanbul: Cinius, 2010.
Encontre o texto completo da fonteBalmer, Sonja. Atemlos: Aufzeichnungen zwischen Beatmungsmaschine, Schläuchen und Computer. 2a ed. Zürich: Limmat Verlag, 2006.
Encontre o texto completo da fonteMassachusetts. Bureau of Environmental Health. Environmental Epidemiology Program. The Amyotrophic Lateral Sclerosis (ALS) Disease Registry: Frequently asked questions for patients and families. Boston, Mass.]: Massachusetts Department of Public Health, Bureau of Environmental Health, Environmental Epidemiology Program, 2009.
Encontre o texto completo da fonteStinton, William M. I choose to live: A journey through life with ALS. Gurnee, IL: Banbury Pub., 2003.
Encontre o texto completo da fonteCapítulos de livros sobre o assunto "Amyotrophic lateral sclerosis – patients"
Cesa-Bianchi, M., e F. Ravaccia. "Psychological Preparation of the Physician for ALS Patients". In Amyotrophic Lateral Sclerosis, 311–12. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_45.
Texto completo da fonteFerro, F. M., G. Riefolo, D. A. Nesci e S. Mazza. "Psychodynamic Aspects in Patients with Amyotrophic Lateral Sclerosis (ALS)". In Amyotrophic Lateral Sclerosis, 313–16. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_46.
Texto completo da fonteNorris, F. H., D. Holden, K. Kandal e E. Stanley. "Home Nursing Care by Families for Severely Paralyzed ALS Patients". In Amyotrophic Lateral Sclerosis, 231–38. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_35.
Texto completo da fonteSinaki, M. "Physical Therapy and Rehabilitation Techniques for Patients with Amyotrophic Lateral Sclerosis". In Amyotrophic Lateral Sclerosis, 239–52. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_36.
Texto completo da fonteDelodovici, M. L., E. Terazzi, C. Pasetti e P. Pinelli. "Analysis of Extrinsic Factors Affecting Pallestesic Threshold (VT) Of Amyotrophic Lateral Sclerosis Patients". In Amyotrophic Lateral Sclerosis, 125–28. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_20.
Texto completo da fontePinelli, P., L. Mazzini, G. Mora, F. Pisano e A. Villani. "A Follow-Up Electromyographic Investigation of ALS Patients Treated with High Dosage Gangliosides". In Amyotrophic Lateral Sclerosis, 285–90. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_41.
Texto completo da fonteMaher, I., A. Pouplard-Barthelaix e J. Emile. "Cytotoxicity of Serum from Amyotrophic Lateral Sclerosis Patients on Spinal Cord Cells in Culture". In Amyotrophic Lateral Sclerosis, 75–77. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_12.
Texto completo da fonteDelwaide, P. J., e J. Schoenen. "Spinal Cord Electrophysiological Activities After Small Doses of TRH in Control Subjects and ALS Patients". In Amyotrophic Lateral Sclerosis, 129–33. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_21.
Texto completo da fonteLane, Giulia, e Paholo Barboglio Romo. "Amyotrophic Lateral Sclerosis and Motor Neuron Disorders". In Urological Care for Patients with Progressive Neurological Conditions, 127–34. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-23277-1_14.
Texto completo da fonteShravani, T., Ramya Sai, M. Vani Shree, J. Amudha e C. Jyotsna. "Assistive Communication Application for Amyotrophic Lateral Sclerosis Patients". In Computational Vision and Bio-Inspired Computing, 1397–408. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-37218-7_147.
Texto completo da fonteTrabalhos de conferências sobre o assunto "Amyotrophic lateral sclerosis – patients"
Aquino, Letícia, Juliana Victor dos Santos, Jaqueline Donola Scandoleira, Jéssica Elen Gonçalves Nascimento e Letícia Moraes de Aquino. "Telerehabilitation in Amyotrophic Lateral Sclerosis". In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.528.
Texto completo da fontePascual Martinez, Natalia, María Melgar Herrero, Cristina Gómez Rebollo e Elisa Martínez Repiso. "How Our Amyotrophic Lateral Sclerosis Patients Die". In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.3419.
Texto completo da fonteVieira, Marina Duarte Gama, Anna Letícia Siqueira de Medeiros, Narayna Suellen Santos da Silva e Edlene Lima Ribeiro. "Dysphagia in patients with amyotrophic lateral sclerosis". In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.398.
Texto completo da fontePyarali, F., R. Lewis, F. Diaz e A. Elsayegh. "Differentiating Spirometric Features Between Patients with Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis". In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2207.
Texto completo da fonteTsai, Jang-Zern, e Tsai-Shih Chen. "Eye-writing communication for patients with amyotrophic lateral sclerosis". In Proceeding of the eleventh international ACM SIGACCESS conference. New York, New York, USA: ACM Press, 2009. http://dx.doi.org/10.1145/1639642.1639694.
Texto completo da fonteEspiritu, Noelle Marie D., Senrong Ainsley C. Chen, Tiffany Ann C. Blasa, Francisco Emmanuel T. Munsayac, Rebecca P. Arenos, Renann G. Baldovino, Nilo T. Bugtai e Homer S. Co. "BCI-controlled Smart Wheelchair for Amyotrophic Lateral Sclerosis Patients". In 2019 7th International Conference on Robot Intelligence Technology and Applications (RiTA). IEEE, 2019. http://dx.doi.org/10.1109/ritapp.2019.8932748.
Texto completo da fonteKurmi, Om Prakash, Manasi Gyanchandani, Nilay Khare e Arvind Pillania. "Classification of Amyotrophic Lateral Sclerosis Patients using speech signals". In 2023 Third International Conference on Secure Cyber Computing and Communication (ICSCCC). IEEE, 2023. http://dx.doi.org/10.1109/icsccc58608.2023.10176797.
Texto completo da fonteHuang, Yixiao, Xiaoli Wu e Rosa H. M. Chan. "Stratification and Survival Prediction for Amyotrophic Lateral Sclerosis Patients". In 2022 IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI). IEEE, 2022. http://dx.doi.org/10.1109/bhi56158.2022.9926946.
Texto completo da fonteKasi, Patrick K., Lisa S. Krivickas, Melvin Meister, Effie Chew, Maurizio Schmid, Gary Kamen, Edward A. Clancy e Paolo Bonato. "Motor unit firing characteristics in patients with amyotrophic lateral sclerosis". In 2009 IEEE 35th Annual Northeast Bioengineering Conference. IEEE, 2009. http://dx.doi.org/10.1109/nebc.2009.4967680.
Texto completo da fonteDalla Vecchia, Laura, Anna Lucini, Domenico Volza, Riccardo Sideri, Kalliopi Marinou e Gabriele Mora. "Cardiac neural regulation involvement in patients with amyotrophic lateral sclerosis". In 2014 8th Conference of the European Study Group on Cardiovascular Oscillations (ESGCO). IEEE, 2014. http://dx.doi.org/10.1109/esgco.2014.6847539.
Texto completo da fonteRelatórios de organizações sobre o assunto "Amyotrophic lateral sclerosis – patients"
Santos, Ana Lúcia Yaeko da Silva, Deyse Mayara Rodrigues Caron, Livia Shirahige e Abrahão Fontes Baptista. Alterations in Corticomotor Excitability in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, maio de 2023. http://dx.doi.org/10.37766/inplasy2023.5.0078.
Texto completo da fonteAnklesaria, Pervin. Preclinical Development of Therapeutics for Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, outubro de 2009. http://dx.doi.org/10.21236/ada541412.
Texto completo da fonteConnor, James R. Apo-Ferritin as a Therapeutic Treatment for Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, setembro de 2012. http://dx.doi.org/10.21236/ada567828.
Texto completo da fontePrzedborski, Serge. Neuroprotective Small Molecules for the Treatment of Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, setembro de 2012. http://dx.doi.org/10.21236/ada567841.
Texto completo da fonteConnor, James R. Apo-Ferritin as a Therapeutic Treatment for Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, dezembro de 2013. http://dx.doi.org/10.21236/ada598852.
Texto completo da fonteGrill, Raymond J. Targeted Riluzole Delivery by Antioxidant Nanovectors for Treating Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, outubro de 2014. http://dx.doi.org/10.21236/ada613439.
Texto completo da fonteGrill, Raymond J. Targeted Riluzole Delivery by Antioxidant Nanovectors for Treating Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, outubro de 2013. http://dx.doi.org/10.21236/ada598451.
Texto completo da fonteLoGrasso, Philip, e Serge Przedborski. c-jun-N-Terminal Kinase (JNK) for the Treatment of Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, outubro de 2013. http://dx.doi.org/10.21236/ada596507.
Texto completo da fonteWackerman, Brooke L., B. L. Cox, K. L. Grayson, Shari L. Shanklin e Wilson W. McGriff. Case Series Investigation of Amyotrophic Lateral Sclerosis (ALS) Among Former Kelly Air Force Base Workers. Fort Belvoir, VA: Defense Technical Information Center, abril de 2005. http://dx.doi.org/10.21236/ada437518.
Texto completo da fonteZhu, Qiaochu, Jin Zhou, Hai Huang, Jie Han, Biwei Cao, Dandan Xu, Yan Zhao e Gang Chen. Risk factors associated with amyotrophic lateral sclerosis: a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, setembro de 2022. http://dx.doi.org/10.37766/inplasy2022.9.0118.
Texto completo da fonte